FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause Stop medicine if signs and symptoms of liver injury occur

FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause Stop medicine if signs and symptoms of liver injury occur https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due?utm_medium=email&utm_source=govdelivery HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VEOZAH safely and effectively. See full prescribing information for VEOZAH. VEOZAH® (fezolinetant) tablets, for oral use Initial U.S. Approval: 2023 https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf?utm_medium=email&utm_source=govdelivery